← Back to Treatments
🏅 FDA Orphan Designation

TECARTUS�

brexucabtagene autoleucel

Manufacturer: Kite Pharma, Inc.

Indicated for:
Mantle cell lymphomaOrphanPrecursor T-cell acute lymphoblastic leukemia
⚠️

Black Box Warning (Boxed Warning)

A Boxed Warning is the FDA's strongest safety warning — it indicates serious or life-threatening risks identified during clinical trials or post-market surveillance. It does not mean the medication is unsafe for all patients; your prescriber weighs these risks against the benefits for your specific situation. Source: FDA-approved prescribing information.

View full prescribing information on DailyMed (NLM) ↗

FDA-Approved Indications (2)

Mantle cell lymphomaOrphan Designation

TECARTUS� is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL)

Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)

Population: adults

Indications & Usage

1 INDICATIONS AND USAGE TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: TECARTUS is a CD19-directed genetically modified autologous T cell immunotherapy indicated for the treatment of: Adult patients with relapsed or refractory mantle cell lymphoma (MCL). This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). 1.1 Mantle Cell Lymphoma Adult patients with relapsed or refractory mantle cell lymphoma (MCL). This indication is approved under accelerated approval based on overall response rate and durability of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. 1.2 Acute Lymphoblastic Leukemia Adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

💙 Support Programs

View all →
TECARTUS�
Kite Pharma, Inc.
TECARTUS�
Kite Pharma, Inc.

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.